01—Abstract
Summary
Summary of the 8-K filed May 5, 2026. Cited figures are marked; the original filing is the authoritative source.
West Pharmaceutical Services, Inc. held its 2026 Annual Meeting of Shareholders virtually on May 4, 2026, with 66,193,322 shares, representing 91.83%a of the 72,081,610 shares outstanding as of the February 27, 2026 record date, represented at the meeting.
Shareholders elected all eleven director nominees, each to serve until the 2027 Annual Meeting, and approved the non-binding advisory vote on named executive officer compensation. Shareholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026. The shareholder proposal regarding an Independent Board Chair Policy was not approved, with 29,592,488 votes for, 34,245,125 against, and 112,824 abstaining, plus 2,242,885 broker non-votes.
The filing contains no financial results, guidance, or transactions; its substance is limited to the governance outcomes of the annual meeting. Director support varied. Eric M.
Green and Deborah L. V. Keller received the most against votes among nominees, at 4,573,928 and 5,599,392 respectively, while Stephen H.
Lockhart received the fewest against votes, at 470,840. The filing also lists Exhibit 104, the Inline XBRL cover page for the Form 8-K dated May 4, 2026.
02—Key points
Key Highlights
- Annual Meeting held virtually on May 4, 2026; 66,193,322 shares (91.83% of 72,081,610 outstanding as of February 27, 2026) were represented.
- All eleven director nominees were elected to serve until the 2027 Annual Meeting; Stephen H. Lockhart had the fewest against votes (470,840) and Deborah L. V. Keller had the most (5,599,392).
- Shareholders approved the non-binding advisory vote on named executive officer compensation with 60,107,802 for and 3,762,206 against.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for fiscal year 2026, with 58,509,119 for and 7,556,514 against.
- The shareholder proposal for an Independent Board Chair Policy was not approved: 29,592,488 for, 34,245,125 against, and 112,824 abstaining.
- Item 9.01 lists only Exhibit 104, the Inline XBRL cover page for the Form 8-K dated May 4, 2026.
03—Questions
Frequently Asked Questions
When and how was the 2026 Annual Meeting held?
The Annual Meeting of Shareholders was held virtually on May 4, 2026. The record date was February 27, 2026, when there were 72,081,610 shares of common stock outstanding.
How many shares participated in the meeting?
A total of 66,193,322 shares, representing 91.83% of the common stock outstanding, were represented at the Annual Meeting.
Were all director nominees elected?
Yes. All eleven nominees were elected as directors, each to serve until the 2027 Annual Meeting of Shareholders, with the detailed voting tallies reported in the filing.
Did shareholders approve the executive compensation proposal?
Yes. The non-binding advisory vote to approve named executive officer compensation was approved, with 60,107,802 votes for, 3,762,206 against, and 80,429 abstaining.
What happened to the shareholder proposal on an Independent Board Chair Policy?
The proposal was not approved. It received 29,592,488 votes for and 34,245,125 against, with 112,824 abstentions and 2,242,885 broker non-votes.
04—Continue